Fresenius signs biosimilars pipeline agreement with WuXi Biologics
Nov 2 (Reuters) – Fresenius has signed a development agreement for biosimilar drugs with China’s WuXi Biologics, the German healthcare group said on Monday. The agreement gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade, addressing more than €370 billion ($414 billion) in originator sales, it added. • Biosimilar drugs are drugs that are…
Open True Mainstream to compare left, right, and center coverage
1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.